Cargando…

Second Generation Long-Acting Injectable Antipsychotics in Africa: About a Case

INTRODUCTION: Schizophrenia affects people worldwide. In Europe, the advantages of second-generation and long-acting injectable antipsychotics (SG-LAIs) are known and used, supported by scientific evidence. However, somewhere there is limited evidence on this topic. OBJECTIVES: Highlight the improve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galvañ, J., Nguepy-Keubo, F. R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479505/ http://dx.doi.org/10.1192/j.eurpsy.2023.1737

Ejemplares similares

Comparative Efficacy of First and Second Generation long-acting injectable antipsychotic upon schizophrenic patients: a systematic review and network metaanalysis.
por: Medrano, R., et al.
Publicado: (2023)

The use of long-acting injectable antipsychotics in an acute psychiatric unit
por: Ortega-Hernández, G., et al.
Publicado: (2023)

Long-acting injectable antipsychotics during pregnancy: An update
por: Paraschakis, A., et al.
Publicado: (2021)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni, Cristiana, et al.
Publicado: (2016)

Adding Suicide Prevention to the Triple Advantages of Injectable Long-Acting Second-Generation Antipsychotics
por: Pompili, Maurizio
Publicado: (2020)

Second‐generation antipsychotic long‐acting injections in bipolar disorder: Systematic review and meta‐analysis
por: Prajapati, Asta R., et al.
Publicado: (2018)

Comparison of hospitalizations in patients on first generation versus second generation long acting injectable (LAI) antipsychotics
por: Rasool, Seemab, et al.
Publicado: (2021)

Evaluation of oral antipsychotic supplementation of select second-generation long-acting injectable antipsychotics in an acute-care psychiatric setting
por: Alastanos, Jennifer N., et al.
Publicado: (2019)

Analysis of Oral versus Long-acting Injectable Antipsychotics in the Maintenance of Schizophrenia
por: Vasiliu, O.
Publicado: (2022)

Corrigendum: Adding Suicide Prevention to the Triple Advantages of Injectable Long-Acting Second-Generation Antipsychotics
por: Pompili, Maurizio
Publicado: (2020)

The combination of long-acting injectable antipsychotics, a new key in resistant schizophrenia
por: Tascón Guerra, M.F., et al.
Publicado: (2022)

The effect of long-acting injectable antipsychotics on QRISK3 in patients with bipolar disorder and schizophrenia
por: Erbasan, V., et al.
Publicado: (2023)

Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary
por: Takács, P., et al.
Publicado: (2019)

Health resource utilization, costs, and community treatment order status before and after the initiation of second-generation long acting-injectable antipsychotics in patients with schizophrenia in Alberta, Canada
por: Chue, P., et al.
Publicado: (2022)

Preliminary results of a network meta-analysis on the efficacy of long-acting injectable antipsychotics in schizophrenia
por: Medrano, R., et al.
Publicado: (2021)

Long-acting new generation antipsychotics in the maintenance treatment of bipolar disorders
por: Yavuz, E., et al.
Publicado: (2023)

Long-acting new generation antipsychotics in the maintenance treatment of bipolar disorders
por: Yavuz, E., et al.
Publicado: (2022)

Second-Generation Long-Acting Injectable Antipsychotics and the Risk of Treatment Failure in a Population-Based Cohort
por: Janzen, Donica, et al.
Publicado: (2022)

An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use
por: VandenBerg, Amy M.
Publicado: (2022)

Comment on “An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use”
por: Still, Daniel, et al.
Publicado: (2023)

Second Generation Long-Acting Injectable Antipsychotics in Schizophrenia: The Patient’s Subjective Quality of Life, Well-Being, and Satisfaction
por: Brasso, Claudio, et al.
Publicado: (2023)

Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective
por: Přikryl, Radovan, et al.
Publicado: (2012)

Profile of patients undergoing treatment with long-acting injectable antipsychotic drugs in a psychiatry hospital in Portugal
por: Correia, J. R. P., et al.
Publicado: (2023)

PM399. Attitudes toward antipsychotic long-acting injections among patients with Schizophrenia in Japan.
por: Kudo, Shuhei, et al.
Publicado: (2016)

Neutropenia induced by several second-generation antipsychotics :A case report
por: Zarouf, H., et al.
Publicado: (2023)

Teetering on the Edge: Second-Degree Atrioventricular Block Following Long-Acting Second-Generation Antipsychotic
por: Harrisingh, Kamahl, et al.
Publicado: (2023)

The need for efficient long-term neuroleptic treatment in schizophrenic patients and the place of long acting injectable antipsychotics
por: Möller, Hans-Jurgen
Publicado: (2010)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

Prescribing patterns of long-acting injectable antipsychotics in a community setting in South Africa
por: Veyej, Nabila, et al.
Publicado: (2022)

Schizophrenia long-acting antipsychotics initiation index (SLAAII)
por: Ifteni, P., et al.
Publicado: (2021)

F228. EFFECTIVENESS OF PALIPERIDONE PALMITATE VS OTHER LONG-ACTING INJECTABLE (LAI) ANTIPSYCHOTICS – AN ELECTRONIC CASE REGISTER STUDY
por: Patel, Rashmi, et al.
Publicado: (2018)

Hepatitis B infection in the rural area of Dschang, Cameroon: seroprevalence and associated factors
por: Tadongfack, Thomas Djifack, et al.
Publicado: (2020)

Traumatisme et résilience associés à la pandémie de la COVID-19 dans les villes de Bafoussam et de Dschang au Cameroun
por: Mboua, Pierre Célestin, et al.
Publicado: (2021)

Combination treatment with second generation antipsychotics other than clozapine
por: Schmidt-Kraepelin, C.
Publicado: (2021)

Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic
por: Pilon, Dominic, et al.
Publicado: (2017)

F226. CLINICAL FACTORS ASSOCIATED WITH CONTINUATION OF LONG-ACTING INJECTABLE ANTIPSYCHOTIC MEDICATION: RETROSPECTIVE CHART REVIEW
por: Kang, Shi Hyun, et al.
Publicado: (2018)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

Attitudes and perceptions about the use of long-acting injectable antipsychotics among behavioral health practitioners
por: Schwartz, Shaina, et al.
Publicado: (2022)

Representations of long-acting antipsychotics in patients at the Arrazi hospital in Salé Morocco
por: Chebli, H., et al.
Publicado: (2023)

Does prescribing long acting antipsychotic injection increase mortality or morbidity in patients who continue to use illicit drugs?
por: Sud, N.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_98drmm8k1ns9karj2dc2oqa5js